To authentically reflect the innate heterogeneity of a tumor, PDX breast cancer model COH-SC31 was considered a valuable tool to test how the levels of ER, involved in cell cycle progression, affect the tumor response to CDK4/6 inhibitors at the single cell level. Here, CDK4 is linked to breast carcinoma.